Effects of nirmatrelvir/ritonavir on midazolam and dabigatran pharmacokinetics in healthy participants
© 2023 British Pharmacological Society..
AIMS: To evaluate pharmacokinetics (PK) and safety after coadministration of nirmatrelvir/ritonavir or ritonavir alone with midazolam (a cytochrome P450 3A4 substrate) and dabigatran (a P-glycoprotein substrate).
METHODS: PK was studied in 2 phase 1, open-label, fixed-sequence studies in healthy adults. Single oral doses of midazolam 2 mg (n = 12) or dabigatran 75 mg (n = 24) were administered alone and after steady state (i.e. ≥2 days) of nirmatrelvir/ritonavir 300 mg/100 mg and ritonavir 100 mg. Midazolam and dabigatran plasma concentrations and adverse events were analysed for each treatment.
RESULTS: After administration of midazolam with nirmatrelvir/ritonavir (test) or alone (reference), midazolam geometric mean area under the concentration-time curve extrapolated to infinity (AUCinf ) and maximum plasma concentration (Cmax ) increased 14.3-fold and 3.7-fold, respectively. Midazolam coadministered with ritonavir (test) or alone (reference) resulted in 16.5-fold and 3.9-fold increases in midazolam geometric mean AUCinf and Cmax , respectively. After administration of dabigatran with nirmatrelvir/ritonavir (test) or alone (reference), dabigatran geometric mean AUCinf and Cmax increased 1.9-fold and 2.3-fold, respectively. Dabigatran coadministered with ritonavir (test) or alone (reference) resulted in a 1.7-fold increase in dabigatran geometric mean AUCinf and Cmax . Midazolam or dabigatran exposures were generally comparable when coadministered with nirmatrelvir/ritonavir or ritonavir alone, with a slightly higher dabigatran Cmax with nirmatrelvir/ritonavir vs. ritonavir alone. Nirmatrelvir/ritonavir was generally safe when administered with or without midazolam or dabigatran. No serious or severe adverse events were reported.
CONCLUSION: Coadministration of midazolam or dabigatran with nirmatrelvir/ritonavir increased systemic exposure of midazolam or dabigatran. Midazolam exposures were comparable when coadministered with nirmatrelvir/ritonavir or ritonavir alone, suggesting no incremental effect of nirmatrelvir. Dabigatran Cmax was slightly higher when coadministered with nirmatrelvir/ritonavir compared with of ritonavir alone, suggesting a minor incremental effect of nirmatrelvir.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:89 |
---|---|
Enthalten in: |
British journal of clinical pharmacology - 89(2023), 11 vom: 24. Nov., Seite 3352-3363 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Cox, Donna S [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 23.10.2023 Date Revised 25.10.2023 published: Print-Electronic ClinicalTrials.gov: NCT05032950, NCT05064800 Citation Status MEDLINE |
---|
doi: |
10.1111/bcp.15835 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM358554187 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM358554187 | ||
003 | DE-627 | ||
005 | 20231226075009.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1111/bcp.15835 |2 doi | |
028 | 5 | 2 | |a pubmed24n1195.xml |
035 | |a (DE-627)NLM358554187 | ||
035 | |a (NLM)37354048 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Cox, Donna S |e verfasserin |4 aut | |
245 | 1 | 0 | |a Effects of nirmatrelvir/ritonavir on midazolam and dabigatran pharmacokinetics in healthy participants |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 23.10.2023 | ||
500 | |a Date Revised 25.10.2023 | ||
500 | |a published: Print-Electronic | ||
500 | |a ClinicalTrials.gov: NCT05032950, NCT05064800 | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2023 British Pharmacological Society. | ||
520 | |a AIMS: To evaluate pharmacokinetics (PK) and safety after coadministration of nirmatrelvir/ritonavir or ritonavir alone with midazolam (a cytochrome P450 3A4 substrate) and dabigatran (a P-glycoprotein substrate) | ||
520 | |a METHODS: PK was studied in 2 phase 1, open-label, fixed-sequence studies in healthy adults. Single oral doses of midazolam 2 mg (n = 12) or dabigatran 75 mg (n = 24) were administered alone and after steady state (i.e. ≥2 days) of nirmatrelvir/ritonavir 300 mg/100 mg and ritonavir 100 mg. Midazolam and dabigatran plasma concentrations and adverse events were analysed for each treatment | ||
520 | |a RESULTS: After administration of midazolam with nirmatrelvir/ritonavir (test) or alone (reference), midazolam geometric mean area under the concentration-time curve extrapolated to infinity (AUCinf ) and maximum plasma concentration (Cmax ) increased 14.3-fold and 3.7-fold, respectively. Midazolam coadministered with ritonavir (test) or alone (reference) resulted in 16.5-fold and 3.9-fold increases in midazolam geometric mean AUCinf and Cmax , respectively. After administration of dabigatran with nirmatrelvir/ritonavir (test) or alone (reference), dabigatran geometric mean AUCinf and Cmax increased 1.9-fold and 2.3-fold, respectively. Dabigatran coadministered with ritonavir (test) or alone (reference) resulted in a 1.7-fold increase in dabigatran geometric mean AUCinf and Cmax . Midazolam or dabigatran exposures were generally comparable when coadministered with nirmatrelvir/ritonavir or ritonavir alone, with a slightly higher dabigatran Cmax with nirmatrelvir/ritonavir vs. ritonavir alone. Nirmatrelvir/ritonavir was generally safe when administered with or without midazolam or dabigatran. No serious or severe adverse events were reported | ||
520 | |a CONCLUSION: Coadministration of midazolam or dabigatran with nirmatrelvir/ritonavir increased systemic exposure of midazolam or dabigatran. Midazolam exposures were comparable when coadministered with nirmatrelvir/ritonavir or ritonavir alone, suggesting no incremental effect of nirmatrelvir. Dabigatran Cmax was slightly higher when coadministered with nirmatrelvir/ritonavir compared with of ritonavir alone, suggesting a minor incremental effect of nirmatrelvir | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a clinical pharmacology > medication safety | |
650 | 4 | |a pharmacokinetics > cytochrome P450 | |
650 | 4 | |a pharmacokinetics > drug interactions | |
650 | 4 | |a pharmacokinetics > p-glycoprotein | |
650 | 7 | |a Midazolam |2 NLM | |
650 | 7 | |a R60L0SM5BC |2 NLM | |
650 | 7 | |a Ritonavir |2 NLM | |
650 | 7 | |a O3J8G9O825 |2 NLM | |
650 | 7 | |a Dabigatran |2 NLM | |
650 | 7 | |a I0VM4M70GC |2 NLM | |
650 | 7 | |a Cytochrome P-450 CYP3A |2 NLM | |
650 | 7 | |a EC 1.14.14.1 |2 NLM | |
700 | 1 | |a Rehman, Muhammad |e verfasserin |4 aut | |
700 | 1 | |a Khan, Tahira |e verfasserin |4 aut | |
700 | 1 | |a Ginman, Katherine |e verfasserin |4 aut | |
700 | 1 | |a Salageanu, Joanne |e verfasserin |4 aut | |
700 | 1 | |a LaBadie, Robert R |e verfasserin |4 aut | |
700 | 1 | |a Wan, Katty |e verfasserin |4 aut | |
700 | 1 | |a Damle, Bharat |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t British journal of clinical pharmacology |d 1974 |g 89(2023), 11 vom: 24. Nov., Seite 3352-3363 |w (DE-627)NLM000097799 |x 1365-2125 |7 nnns |
773 | 1 | 8 | |g volume:89 |g year:2023 |g number:11 |g day:24 |g month:11 |g pages:3352-3363 |
856 | 4 | 0 | |u http://dx.doi.org/10.1111/bcp.15835 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 89 |j 2023 |e 11 |b 24 |c 11 |h 3352-3363 |